Induction of therapeutic levels of HbF in genome-edited primary β0 39-thalassaemia haematopoietic stem and progenitor cells.

British Journal of Haematology
Maura MingoiaPaolo Moi

Abstract

Hereditary persistence of fetal haemoglobin (HPFH) is the major modifier of the clinical severity of β-thalassaemia. The homozygous mutation c.-196 C>T in the Aγ-globin (HBG1) promoter, which causes Sardinian δβ0 -thalassaemia, is able to completely rescue the β-major thalassaemia phenotype caused by the β0 39-thalassaemia mutation, ensuring high levels of fetal haemoglobin synthesis during adulthood. Here, we describe a CRISPR/Cas9 genome-editing approach, combined with the non-homologous end joining (NHEJ) pathway repair, aimed at reproducing the effects of this naturally occurring HPFH mutation in both HBG promoters. After selecting the most efficient guide RNA in K562 cells, we edited the HBG promoters in human umbilical cord blood-derived erythroid progenitor 2 cells (HUDEP-2) and in haematopoietic stem and progenitor cells (HSPCs) from β0 -thalassaemia patients to assess the therapeutic potential of HbF induction. Our results indicate that small deletions targeting the -196-promoter region restore high levels of fetal haemoglobin (HbF) synthesis in all cell types tested. In pools of HSPCs derived from homozygous β0 39-thalassaemia patients, a 20% editing determined a parallel 20% increase of HbF compared to unedited pools...Continue Reading

References

May 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·M PirastuY W Kan
Jun 1, 1982·Journal of Medical Genetics·A CaoL F Bernini
Aug 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·F S CollinsS M Weissman
Jan 15, 1993·Experientia·A D Adekile, T H Huisman
Mar 1, 1994·Blood Reviews·A CaoM C Rosatelli
Jul 21, 1998·Annals of the New York Academy of Sciences·B G Forget
Feb 15, 2002·Current Opinion in Hematology·Stanley L Schrier
Aug 5, 2008·Current Opinion in Immunology·Effie W Petersdorf
Dec 31, 2008·Journal of Virological Methods·Hitoshi KurodaJakob Reiser
Mar 26, 2009·Current Opinion in Hematology·Stefano Rivella
Jan 1, 2011·Revista brasileira de hematologia e hemoterapia·Gisele Cristine de Souza CarrociniClaudia Regina Bonini-Domingos
Dec 5, 2012·Cold Spring Harbor Perspectives in Medicine·Vijay G Sankaran, Stuart H Orkin
Oct 1, 2013·Nature Methods·Prashant MaliGeorge M Church
Oct 26, 2013·Nature Protocols·F Ann RanFeng Zhang
Oct 11, 2014·Nucleic Acids Research·Eva K BrinkmanBas van Steensel
Nov 6, 2014·Molecular Biotechnology·Wojciech BarczakKatarzyna Kulcenty
Nov 29, 2014·Science·Jennifer A Doudna, Emmanuelle Charpentier
Sep 4, 2016·Journal of Translational Medicine·Lucia Carmela CosenzaNicoletta Bianchi
Sep 8, 2016·Proceedings of the National Academy of Sciences of the United States of America·Lin YeYuet Wai Kan
Nov 2, 2016·Expert Review of Hematology·Orapan Sripichai, Suthat Fucharoen
Jun 28, 2017·Blood Cells, Molecules & Diseases·Swee Lay Thein
Jul 1, 2017·Blood·Beeke WienertMerlin Crossley
Jan 16, 2018·F1000Research·Eitan Fibach, Eliezer A Rachmilewitz
Nov 15, 2018·Molecular Therapy : the Journal of the American Society of Gene Therapy·Annalisa LattanziAnnarita Miccio

❮ Previous
Next ❯

Citations

Oct 11, 2021·Molecular Therapy : the Journal of the American Society of Gene Therapy·Tolulope O Rosanwo, Daniel E Bauer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.